Pricing
  1. US-listed companies
  2. Emergent BioSolutions Inc.
  3. Financials
  4. Revenue

Emergent BioSolutions Inc. (EBS)

Market cap
$446.71M
P/E ratio
SummaryFinancials
Period EndRevenue (Million USD)YoY (%)
Dec 31, 20241,044-0.54%
Dec 31, 20231,049-6.39%
Dec 31, 20221,121-37.47%
Dec 31, 20211,793+15.26%
Dec 31, 20201,555+40.63%
Dec 31, 20191,106+41.36%
Dec 31, 2018782+39.50%
Dec 31, 2017561+14.75%
Dec 31, 2016489-6.50%
Dec 31, 2015523+67.16%
Dec 31, 2013313+10.95%
Dec 31, 2012282+3.11%
Dec 31, 2011273

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat